COMMUNIQUÉS West-GlobeNewswire
-
Proxygen Appoints Chiara Conti, Ph.D. as Chief Scientific Officer to Drive Clinical Translation and Expand Induced Proximity Platform Beyond Degradation
31/03/2026 -
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
31/03/2026 -
electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
31/03/2026 -
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
31/03/2026 -
Stryker names Nick Mead Vice President, Investor Relations
31/03/2026 -
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
31/03/2026 -
Anathapindika Shines Spotlight on Detoxification During National Nutrition Month
31/03/2026 -
Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies
31/03/2026 -
MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation
31/03/2026 -
Pheast Therapeutics Advances PHST001, an IgG4 Anti-CD24 Monoclonal Antibody, into Phase 1b Combination Cohorts
31/03/2026 -
Annovis Publishes Historical Review of Buntanetap in The Scientist
31/03/2026 -
Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
31/03/2026 -
YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States
31/03/2026 -
Weight Watchers Announces Best in Market Self-Pay Wegovy® Pricing for Med+ Members and the Launch of Preferred Subscription Pricing for Wegovy via NovoCare®
31/03/2026 -
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
31/03/2026 -
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
31/03/2026 -
MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
31/03/2026 -
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
31/03/2026 -
BrightSpring Health Services Completes Sale of ResCare Community Living to Sevita
31/03/2026
Pages